• Home
• About Us
  • Overview
  • Management
  • Board of Directors
  • Partners
  • Dynavax Europe
• Pipeline
  • Overview
  • HEPLISAV
  • Asthma
  • Autoimmunity / Inflammation
• Technology
  • Immune System
  • ISS
  • IRS
  • Publications
• Investors
  • Overview
  • News & Events
  • Stock Information
  • Analyst Coverage
  • Financials
  • SEC Filings
  • Corporate Governance
  • Contact Us
• Careers
• Contact Us

About Us

Overview
Management
Board of Directors

Partners
Dynavax Europe

About Us :: Overview

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Our lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. A BLA for HEPLISAV has been accepted for review by the FDA , and an MAA has been accepted for review in Europe by the EMA.

Our clinical-stage product candidates include:

• Phase 3 HEPLISAV ™ Hepatitis B Vaccine
• Phase 1 TLR Inhibitor for Lupus
• Phase 1 Asthma Therapy

We have programs partnered with pharmaceutical companies, including AstraZeneca and GlaxoSmithKline.

Our European subsidiary Rhein Biotech manufactures hepatitis B surface antigen for HEPLISAV.  With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.